Skip to main content
SpringerLink
Log in

Systemic Toxicity of Drugs Applied to the Eye

  • Chapter
  • First Online:
Pharmacology of Ocular Therapeutics

  • 1627 Accesses

Abstract

When a drug is administered to treat, diagnose or mitigate any ocular condition, it may produce certain undesirable effects besides the desirable or therapeutic one. When a drug is administered systemically, its absorption in the eye is restricted by various factors including the ocular barriers. Still, certain drugs are able to breach this barrier and thus can cause toxicity. Similarly, drugs given topically or by the invasive ocular route can cross the blood ocular barrier to cause systemic toxicity. This chapter discusses the systemic toxicity of drugs applied on eye including the anti-glaucoma agents, drugs acting on autonomic nervous system, anti-inflammatory agents, antimicrobial agents, drugs used for ocular neovascularization conditions and preservatives used in ophthalmic preparations. This chapter also briefly describes about the ocular toxicity caused by the systemically administered drugs.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 39.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 54.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 54.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  • Amon RB, Lis AW, Hanifin JM. Allergic contact dermatitis caused by idoxuridine. Patterns of cross reactivity with other pyrimidine analogues. Arch Dermatol. 1975;111(12):1581–4.

    Article  PubMed  CAS  Google Scholar 

  • Aoki J. [Allergic contact dermatitis due to eye drops. Their clinical features and the patch test results]. Nihon Ika Daigaku Zasshi. 1997;64(3):232–7.

    Article  PubMed  CAS  Google Scholar 

  • Bahar I, Vinker S, Kaisrman I. The effect of topical steroids on blood glucose profile in diabetic patients. J Clin Experiment Ophthalmol. 2011;2(2):1–3.

    Article  Google Scholar 

  • Bartlett JD, Jaanus SD. Drug affecting the autonomic nervous system. Clinical ocular pharmacology. 2nd ed. Butterworth-Heinemann, Reed Publishing, USA; 1989.

    Google Scholar 

  • Beasley CR, Rafferty P, Holgate ST. Bronchoconstrictor properties of preservatives in ipratropium bromide (Atrovent) nebuliser solution. Br Med J. 1987;294(6581):1197–8.

    Article  CAS  Google Scholar 

  • Bowman RJ, Cope J, Nischal KK. Ocular and systemic side effects of brimonidine 0.2% eye drops (Alphagan) in children. Eye. 2004;18(1):24–6.

    Article  PubMed  CAS  Google Scholar 

  • Cirkel PK, van Ketel WG. Allergic contact dermatitis to trifluorothymidine eyedrops. Contact Dermatitis. 1981;7(1):49–50.

    Article  PubMed  CAS  Google Scholar 

  • Duvall B, Kershner R. Ocular side effects of systemically administered medications. Ophthalmic medications and pharmacology. 2nd ed. SLACK incorporated, USA; 2006

    Google Scholar 

  • Eggleston ST, Lush LW. Understanding allergic reactions to local anesthetics. Ann Pharmacother. 1996;30(7–8):851–7.

    PubMed  CAS  Google Scholar 

  • Enyedi LB, Freedman SF. Safety and efficacy of brimonidine in children with glaucoma. J AAPOS. 2001;5(5):281–4.

    Article  PubMed  CAS  Google Scholar 

  • Epstein SP, Ahdoot M, Marcus E, Asbell PA. Comparative toxicity of preservatives on immortalized corneal and conjunctival epithelial cells. J Ocul Pharmacol Ther. 2009;25(2):113–9.

    Article  PubMed Central  PubMed  CAS  Google Scholar 

  • Everitt DE, Avorn J. Systemic effects of medications used to treat glaucoma. Ann Intern Med. 1990;112(2):120–5.

    Article  PubMed  CAS  Google Scholar 

  • Fraunfelder FT, Meyer SM. Systemic reactions to ophthalmic drug preparations. Med Toxicol Adverse Drug Exp. 1987;2(4):287–93.

    PubMed  CAS  Google Scholar 

  • Gaynes BI, Fiscella R. Topical nonsteroidal anti-inflammatory drugs for ophthalmic use: a safety review. Drug Saf. 2002;25(4):233–50.

    Article  PubMed  CAS  Google Scholar 

  • Gaynor BD, Chidambaram JD, Cevallos V, Miao Y, Miller K, Jha HC, et al. Topical ocular antibiotics induce bacterial resistance at extraocular sites. Br J Ophthalmol. 2005;89(9):1097–9.

    Article  PubMed Central  PubMed  CAS  Google Scholar 

  • Gokulgandhi MR, Vadlapudi AD, Mitra AK. Ocular toxicity from systemically administered xenobiotics. Expert Opin Drug Metab Toxicol. 2012;8(10):1277–91.

    Article  PubMed Central  PubMed  CAS  Google Scholar 

  • Goldberg I, Moloney G, McCluskey P. Topical ophthalmic medications: what potential for systemic side effects and interactions with other medications? Med J Aust. 2008;189(7):356–7.

    PubMed  Google Scholar 

  • Gottschalk HR, Stone OJ. Stevens-Johnson syndrome from ophthalmic sulfonamide. Arch Dermatol. 1976;112(4):513–4.

    Article  PubMed  CAS  Google Scholar 

  • Holdiness MR. Contact dermatitis from topical antiviral drugs. Contact Dermatitis. 2001;44(5):265–9.

    Article  PubMed  CAS  Google Scholar 

  • Hwang DJ, Kim YW, Woo SJ, Park KH. Comparison of systemic adverse events associated with intravitreal anti-VEGF injection: ranibizumab versus bevacizumab. J Korean Med Sci. 2012;27(12):1580–5.

    Article  PubMed Central  PubMed  CAS  Google Scholar 

  • Kanski JJ. Mydriatics. Br J Ophthalmol. 1969;53(6):428–9.

    Article  PubMed Central  PubMed  CAS  Google Scholar 

  • Lama PJ. Systemic adverse effects of beta-adrenergic blockers: an evidence-based assessment. Am J Ophthalmol. 2002;134(5):749–60.

    Article  PubMed  CAS  Google Scholar 

  • Laporte JR, Vidal X, Ballarin E, Ibanez L. Possible association between ocular chloramphenicol and aplastic anaemia – the absolute risk is very low. Br J Clin Pharmacol. 1998;46(2):181–4.

    Article  PubMed Central  PubMed  CAS  Google Scholar 

  • Mackie BS, Mackie LE. Systemic lupus erythematosus – dermatomyositis induced by sulphacetamide eye drops. Australas J Dermatol. 1979;20(1):49–50.

    Article  PubMed  CAS  Google Scholar 

  • Mezger E, Wendler O, Mayr S, Bozzato A. Anaphylactic reaction following administration of nose drops containing benzalkonium chloride. Head Face Med. 2012;8:29.

    Article  PubMed Central  PubMed  Google Scholar 

  • Millan-Parrilla F, de la Cuadra J. Allergic contact dermatitis from trifluridine in eyedrops. Contact Dermatitis. 1990;22(5):289.

    Article  PubMed  CAS  Google Scholar 

  • Ozerdem U, Levi L, Cheng L, Song MK, Scher C, Freeman WR. Systemic toxicity of topical and periocular corticosteroid therapy in an 11-year-old male with posterior uveitis. Am J Ophthalmol. 2000;130(2):240–1.

    Article  PubMed  CAS  Google Scholar 

  • Picado C. Mechanisms of aspirin sensitivity. Current allergy and asthma reports. 2006;6(3):198–202.

    Google Scholar 

  • Quigley HA, Broman AT. The number of people with glaucoma worldwide in 2010 and 2020. Br J Ophthalmol. 2006;90(3):262–7.

    Article  PubMed Central  PubMed  CAS  Google Scholar 

  • Rajan MS, Syam P, Liu C. Systemic side effects of topical latanoprost. Eye. 2003;17(3):442–4.

    Article  PubMed  CAS  Google Scholar 

  • Reilly KM, Chan L, Mehta NJ, Salluzzo RF. Systemic toxicity from ocular homatropine. Acad Emer Med. 1996;3(9):868–71.

    Article  CAS  Google Scholar 

  • Rubin AP. Complications of local anaesthesia for ophthalmic surgery. Br J Anaesth. 1995;75(1):93–6.

    Article  PubMed  CAS  Google Scholar 

  • Semeraro F, Morescalchi F, Parmeggiani F, Arcidiacono B, Costagliola C. Systemic adverse drug reactions secondary to anti-VEGF intravitreal injection in patients with neovascular age-related macular degeneration. Curr Vasc Pharmacol. 2011;9(5):629–46.

    Article  PubMed  CAS  Google Scholar 

  • Sharir M. Exacerbation of asthma by topical diclofenac. Arch Ophthalmol. 1997;115(2):294–5.

    Article  PubMed  CAS  Google Scholar 

  • Shiuey Y, Eisenberg MJ. Cardiovascular effects of commonly used ophthalmic medications. Clin Cardiol. 1996;19(1):5–8.

    Article  PubMed  CAS  Google Scholar 

  • Soni MG, Taylor SL, Greenberg NA, Burdock GA. Evaluation of the health aspects of methyl paraben: a review of the published literature. Food Chem Toxicol. 2002;40(10):1335–73.

    Article  PubMed  CAS  Google Scholar 

  • US-FDA. Nonclinical safety evaluation of reformulated drug products and products intended for administration by an alternate route. In: FDA, editor. Rockville: Center for Drug Evaluation and Research, Food and Drug Administration; 2008. p. 1–8.

    Google Scholar 

  • Vijayakumar AR, Velpandian T, Saxena R. Ocular adverse effects of systemically administered drugs. In: Agarwal R, Agarwal P, (ed.). Essentials of ocular pharmacology. Malaysia: University Publication Centre (UPENA); 2011;1:343–64.

    Google Scholar 

  • Wang W, Zhang X. Systemic adverse events after intravitreal bevacizumab versus ranibizumab for age-related macular degeneration: a meta-analysis. PLoS One. 2014;9(10):e109744.

    Article  PubMed Central  PubMed  CAS  Google Scholar 

  • Wiholm BE, Kelly JP, Kaufman D, Issaragrisil S, Levy M anderson T, et al. Relation of aplastic anaemia to use of chloramphenicol eye drops in two international case–control studies. BMJ. 1998;316(7132):666.

    Google Scholar 

  • Wu L, Martinez-Castellanos MA, Quiroz-Mercado H, Arevalo JF, Berrocal MH, Farah ME, et al. Twelve-month safety of intravitreal injections of bevacizumab (Avastin): results of the Pan-American Collaborative Retina Study Group (PACORES). Graefe’s archive for clinical and experimental ophthalmology. Albrecht Von Graefes Arch Klin Exp Ophthalmol. 2008;246(1):81–7.

    Article  CAS  Google Scholar 

  • Zimmerman TJ, Wheeler TM. Miotics: side effects and ways to avoid them. Ophthalmology. 1982;89(1):76–80.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Ocular Pharmacology and Pharmacy, Dr. Rajendra Prasad Center for Ophthalmic Sciences, All India Institute of Medical Sciences, New Delhi, India

    Hanuman Prasad Sharma M. Pharm & Thirumurthy Velpandian BPharm, MS(Pharmacol), PhD

  2. Ophthalmic Pharmaceutical Division, Appasamy Associates, Arumbakkam, Chennai, India

    Arumugam Ramamoorthy Vijayakumar PhD

Authors
  1. Hanuman Prasad Sharma M. Pharm
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Arumugam Ramamoorthy Vijayakumar PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Thirumurthy Velpandian BPharm, MS(Pharmacol), PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Thirumurthy Velpandian BPharm, MS(Pharmacol), PhD .

Editor information

Editors and Affiliations

  1. Ocular Pharmacology and Pharmacy, Dr. RP Centre for Ophthalmic Sciences, New Delhi, India

    Thirumurthy Velpandian

Rights and permissions

Reprints and permissions

Copyright information

© 2016 Springer International Publishing Switzerland

About this chapter

Cite this chapter

Sharma, H.P., Vijayakumar, A.R., Velpandian, T. (2016). Systemic Toxicity of Drugs Applied to the Eye. In: Velpandian, T. (eds) Pharmacology of Ocular Therapeutics. Adis, Cham. https://doi.org/10.1007/978-3-319-25498-2_14

Download citation

Publish with us

Policies and ethics

Search

Navigation